• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.

作者信息

Lim Jaegyun, Jeon Seunghyun, Shin Hyun Young, Kim Moon Jung, Seong Yu Min, Lee Wang Jun, Choe Kang Won, Kang Yu Min, Lee Baeckseung, Park Sang Joon

机构信息

Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.

New Horizon Cancer Institute, Myongji Hospital, Goyang, Korea.

出版信息

J Korean Med Sci. 2020 Feb 24;35(7):e89. doi: 10.3346/jkms.2020.35.e89.

DOI:10.3346/jkms.2020.35.e89
PMID:32080993
Abstract
摘要

相似文献

1
The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.作者回应：韩国首例导致新型冠状病毒肺炎三代传播病例：洛匹那韦/利托那韦用于治疗经定量逆转录聚合酶链反应监测的新型冠状病毒肺炎
J Korean Med Sci. 2020 Feb 24;35(7):e89. doi: 10.3346/jkms.2020.35.e89.
2
Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.致编辑的信：韩国首例导致新型冠状病毒肺炎三代传播的病例：洛匹那韦/利托那韦在定量逆转录聚合酶链反应监测下治疗新型冠状病毒肺炎的应用
J Korean Med Sci. 2020 Feb 24;35(7):e88. doi: 10.3346/jkms.2020.35.e88.
3
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.韩国第三代 COVID-19 感染传播者索引患者病例：应用洛匹那韦/利托那韦定量 RT-PCR 监测 COVID-19 感染肺炎的治疗。
J Korean Med Sci. 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79.
4
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.达芦那韦不能预防HIV患者感染SARS-CoV-2。
Pharmacol Res. 2020 Jul;157:104826. doi: 10.1016/j.phrs.2020.104826. Epub 2020 Apr 20.
5
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.洛匹那韦利托那韦治疗的 2 例 COVID-19 患者出现血清素综合征。
J Neurol Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944. Epub 2020 May 27.
6
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
7
Lopinavir-ritonavir in severe COVID-19.洛匹那韦-利托那韦治疗重症新型冠状病毒肺炎
Nat Med. 2020 Apr;26(4):465. doi: 10.1038/s41591-020-0849-9.
8
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
9
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.评价法维拉韦和干扰素与洛匹那韦/利托那韦和干扰素在 COVID-19 中度患者中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 27;21(1):886. doi: 10.1186/s13063-020-04747-8.
10
A Trial of Lopinavir-Ritonavir in Covid-19. Reply.洛匹那韦-利托那韦治疗新冠肺炎的试验。回复。
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.

引用本文的文献

1
Application of artificial intelligence (AI) to control COVID-19 pandemic: Current status and future prospects.人工智能在控制新冠疫情中的应用：现状与未来前景
Heliyon. 2024 Feb 9;10(4):e25754. doi: 10.1016/j.heliyon.2024.e25754. eCollection 2024 Feb 29.
2
Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics.基于分子对接和分子动力学的N-0385阻断严重急性呼吸综合征冠状病毒2治疗冠状病毒病19的机制
Front Microbiol. 2022 Oct 18;13:1013911. doi: 10.3389/fmicb.2022.1013911. eCollection 2022.
3
SUFEMO: A superpixel based fuzzy image segmentation method for COVID-19 radiological image elucidation.
SUFEMO：一种基于超像素的模糊图像分割方法，用于阐明COVID-19放射图像。
Appl Soft Comput. 2022 Nov;129:109625. doi: 10.1016/j.asoc.2022.109625. Epub 2022 Sep 15.
4
The epidemiology and therapeutic options for the COVID-19.新型冠状病毒肺炎的流行病学及治疗选择
Precis Clin Med. 2020 Jun;3(2):71-84. doi: 10.1093/pcmedi/pbaa017. Epub 2020 May 28.
5
In vitro Anti SARS-CoV-2 Activity and Docking Analysis of , and Edible Mushrooms.香菇、平菇和金针菇的体外抗新型冠状病毒 2 活性及对接分析
Infect Drug Resist. 2022 Jul 2;15:3459-3475. doi: 10.2147/IDR.S362823. eCollection 2022.
6
"How are You Doing?" on the Healthy Aging of the Community-Dwelling Oldest-Old in the Shadow of the COVID-19 Pandemic.“您最近过得怎么样？”在 COVID-19 大流行的阴影下，社区居住的最年长老年人的健康老龄化。
Res Aging. 2023 Mar;45(3-4):280-290. doi: 10.1177/01640275221100949. Epub 2022 May 18.
7
Psychological impact of COVID-19 pandemic: A cross-sectional study of hospitalized COVID-19 patients in an urban setting, Bangladesh.2019冠状病毒病疫情的心理影响：孟加拉国城市地区住院的2019冠状病毒病患者的横断面研究
Heliyon. 2022 Mar 12;8(3):e09110. doi: 10.1016/j.heliyon.2022.e09110. eCollection 2022 Mar.
8
Theory and reality of antivirals against SARS-CoV-2.抗2019冠状病毒病抗病毒药物的理论与现实
World J Clin Cases. 2021 Aug 16;9(23):6663-6673. doi: 10.12998/wjcc.v9.i23.6663.
9
Evaluation of dyspnea severity and sleep quality in patients with novel coronavirus.评估新型冠状病毒感染患者呼吸困难严重程度和睡眠质量。
Int J Clin Pract. 2021 Oct;75(10):e14631. doi: 10.1111/ijcp.14631. Epub 2021 Jul 20.
10
Current evidence for directed and supportive investigational therapies against COVID-19.针对新型冠状病毒肺炎（COVID-19）的定向和支持性研究性治疗的当前证据。
Afr J Thorac Crit Care Med. 2020 Apr 30;26(2). doi: 10.7196/AJTCCM.2020.v26i2.072. eCollection 2020.